How TKI treatment affects thyroid in CML patients
Part of Blood & lymphatic, Cancer, Immune system & allergy, Lungs & breathing clinical trials.
This trial looks at how a targeted therapy called TKI (tyrosine kinase inhibitor) affects thyroid function in patients newly diagnosed with chronic myeloid leukemia (CML). It aims to understand any changes in the thyroid gland during treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have been newly diagnosed with CML and have a specific genetic marker called the Philadelphia chromosome.
- You have never taken a TKI before.
- You do not have a history of thyroid problems or take medication for thyroid issues.
- You are not pregnant or breastfeeding, and you are not taking oral contraceptive pills or corticosteroids.
- You are not taking certain drugs like dexamethasone, phenytoin, carbamazepine, rifampin, or phenobarbital.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tracks the experiences and health outcomes of people with chronic myeloid leukemia (CML) who are taking approved first or second line tyrosine kinase inhibitor (TKI) medicines. It helps doctors learn how these treatments work in everyday care.
This study examines whether a new type of cancer medication affects thinking, memory, and focus in people with chronic myeloid leukemia (CML) or chronic lymphocytic leukemia (CLL). Researchers will compare people starting this medication with healthy volunteers to understand any changes.
This trial looks at how gut bacteria affect the way chronic myeloid leukemia (CML) patients respond to tyrosine kinase inhibitor (TKI) medications. It may help doctors understand why some people have better outcomes than others.
This study looks at whether tyrosine kinase inhibitors (TKIs), a common treatment for chronic myeloid leukemia (CML), are linked to erectile dysfunction in men. It aims to help patients and doctors understand possible side effects.
This trial is testing a new, highly sensitive blood test (digital PCR) to find BCR::ABL1 mutations in people with chronic-phase CML who are switching their tyrosine kinase inhibitor (TKI) because of resistance or a warning sign. The goal is to see if this test can help guide treatment decisions more precisely.
This trial looks at how well children with chronic myeloid leukemia (CML) respond to standard “TKI” tablets when treatment starts. It uses genetic test results from diagnosis (DNA/RNA) to understand which children respond better and why.
Hear when a new Leukaemia (Chronic) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.